PRVA Stock Recent News
PRVA LATEST HEADLINES
Privia Health Group, Inc. (NASDAQ:PRVA ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Robert Borchert - Senior Vice President-Investor and Corporate Communications Parth Mehrotra - Chief Executive Officer David Mountcastle - Chief Financial Officer Conference Call Participants Jailendra Singh - Truist Josh Raskin - Nephron Research Richard Close - Canaccord Matthew Gillmor - KeyBanc Jessica Tassan - Piper Sandler Alberta Massey - Leerink Partners A.J. Rice - UBS Thomas Walsh - Barclays Ryan Langston - TD Cowen Elizabeth Anderson - Evercore ISI Constantine Davides - Citizens JMP Jack Slevin - Jefferies Jeff Garro - Stephens Ryan Daniels - William Blair David Larsen - BTIG Matt Shea - Needham Jamie Perse - Goldman Sachs Daniel Grosslight - Citi Michael Ha - Baird Joanna Gajuk - Bank of America Operator Thank you for standing by.
While the top- and bottom-line numbers for Privia Health (PRVA) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Privia Health (PRVA) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.02 per share a year ago.
Strong First Quarter Performance and Operating Execution Enters the State of Arizona Full-Year 2025 Outlook Raised to Mid- to High End of Guidance Ranges for All Metrics with Attributed Lives Unchanged ARLINGTON, Va., May 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the first quarter ended March 31, 2025.
Get a deeper insight into the potential performance of Privia Health (PRVA) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
With the broader market facing volatility, a clutch of experts are recommending investors to look beyond mega-cap stocks like Meta, Amazon, and Netflix for opportunities in stocks with strong earnings growth potential.
Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Privia Health Group, Inc. (NASDAQ:PRVA ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Robert Borchert - Senior Vice President-Investor & Corporate Communications Parth Mehrotra - Chief Executive Officer David Mountcastle - Chief Financial Officer Conference Call Participants Sameer Patel - Evercore ISI Andrew Mok - Barclays Josh Raskin - Nephron Research Whit Mayo - Leerink Partners Jailendra Singh - Truist Securities A.J. Rice - UBS Jack Slevin - Jeffries Jeff Garro - Stephens Inc Matthew Gillmor - KeyBanc Richard Close - Canaccord Genuity Matt Shea - Needham Ryan Langston - TD Cowen David Larsen - BTIG Adam Ron - Bank of America Michael Ha - Baird Constantine Davides - Citizens JMP Daniel Grosslight - Citi Jessica Tassan - Piper Sandler Tao Qiu - Macquarie Craig Jones - Stifel Operator Thank you for standing by.
Privia Health (PRVA) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.02 per share a year ago.
All 2024 Operating and Financial Metrics Above High End of Guidance Ranges Very strong New Provider Signings with Implemented Providers +11.2% from Year-end 2023 Full-year 2024 Net Cash Provided by Operating Activities of $109.3 million, +35.3% from 2023, with De Minimis Capital Expenditures Year-end 2024 Cash Balance of $491.1 million and No Debt 2025 Guidance Reflects Continued Momentum and Profitable Growth Despite Challenging Medicare Advantage and Value-based Environment ARLINGTON, Va., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial and operating results for the fourth quarter and full year ended December 31, 2024.